KORU Medical Systems develops, manufactures, and commercializes innovative and patient-centric large volume subcutaneous infusion solutions that improve quality of life for patients around the world.

Surf Bio, a biopharmaceutical company transforming the delivery of antibodies and biologics, announced today that a peer-reviewed study conducted by researchers at Stanford University and published in ...

Compared with oral administration, continuous subcutaneous infusion of carbidopa/levodopa was linked to nearly 2 more hours of “on” time without dyskinesia in adults with Parkinson’s disease ...

KORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on development, manufacturin ...

These results, with the KORU Freedom Infusion System, also demonstrate the company’s potential to support a broader range of developmental subcutaneous drug therapies.” About KORU Medical Systems ...

KORU Medical Systems, Inc., a leading medical technology company focused on development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion ...

The prospective study, which was conducted between June 2, 2017, and June 10, 2020, combined an intrathecal catheter and power injectable infusion port, both FDA-approved devices, to create the ...

Key Takeaways The subcutaneous formulation of Opdivo provides a convenient alternative to intravenous administration for patients with solid tumors, maintaining efficacy and safety. The CHECKMATE-67T ...

Researchers reported calculated geometric mean ratios comparing subcutaneous vs. intravenous administration for C trough of 1.15 (90% CI, 1.04-1.26) for C2D1 and 1.43 (90% CI, 1.27-1.61) for C4D1.

Tyenne is supplied as a 20mg/mL single-dose vial (80mg/4mL, 200mg/10mL, or 400mg/20mL) for further dilution prior to IV infusion.

In December 2024, the Food and Drug Administration (FDA) approved the PD-1 inhibitor nivolumab (Opvido Qvantig) for use as a subcutaneous injection.